Clinical Trials Logo

High Risk MDS or AML Patients clinical trials

View clinical trials related to High Risk MDS or AML Patients.

Filter by:
  • None
  • Page 1

NCT ID: NCT02233504 Completed - Clinical trials for High Risk MDS or AML Patients

Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

Start date: August 2014
Phase: Early Phase 1
Study type: Interventional

The purpose of this trial is to examine the hematologic response rate of Exjade® in patients with AML and high risk MDS and chronic iron overload from blood transfusions. Deferasirox has been developed as an iron-chelating agent, and unlike deferoxamine, a previously developed iron chelator, deferasirox has the advantage of oral administration.